ARC-AAT Injection
Phase 2Withdrawn 0 watching 0 views this week⚡ Active
49
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Alpha-1 Antitrypsin Deficiency
Conditions
Alpha-1 Antitrypsin Deficiency
Trial Timeline
Oct 1, 2016 → Nov 1, 2016
NCT ID
NCT02900183About ARC-AAT Injection
ARC-AAT Injection is a phase 2 stage product being developed by Arrowhead Pharmaceuticals for Alpha-1 Antitrypsin Deficiency. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT02900183. Target conditions include Alpha-1 Antitrypsin Deficiency.
Hype Score Breakdown
Clinical
17
Activity
12
Company
7
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02900183 | Phase 2 | Withdrawn |
Competing Products
13 competing products in Alpha-1 Antitrypsin Deficiency
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Drug-Carbamazepine (Tegretol XR) + Carbamazepine (Tegretol XR) Placebo | Novartis | Phase 2 | 52 |
| VX-668 + Placebo | Vertex Pharmaceuticals | Phase 1 | 32 |
| VX-864 | Vertex Pharmaceuticals | Phase 2 | 51 |
| ALN-AAT02 + Placebo + ALN-AAT02 | Alnylam Pharmaceuticals | Phase 1/2 | 38 |
| ARC-AAT Injection + Diphenhydramine | Arrowhead Pharmaceuticals | Phase 1 | 30 |
| Alpha-1 MP | Grifols | Phase 3 | 74 |
| Alpha-1 MP | Grifols | Phase 3 | 74 |
| WVE-006 | WaVe Life Sciences | Phase 1 | 28 |
| WVE-006 | WaVe Life Sciences | Phase 1/2 | 36 |
| INBRX-101/rhAAT-Fc | Inhibrx Biosciences | Phase 1 | 28 |
| Kamada-AAT for Inhalation, 80mg + Placebo + Kamada-AAT for Inhalation, 160mg | Kamada | Phase 2 | 44 |
| KRRO-110 | Korro Bio | Phase 1/2 | 33 |
| Alvelestat (MPH966) | Mereo BioPharma | Phase 2 | 44 |